Therapeutic drug monitoring to adjust dosing in morbid obesity - A new use for an old methodology

Martin, Jennifer H., Saleem, Mohamed and Looke, David (2012) Therapeutic drug monitoring to adjust dosing in morbid obesity - A new use for an old methodology. British Journal of Clinical Pharmacology, 73 5: 685-690. doi:10.1111/j.1365-2125.2011.04159.x


Author Martin, Jennifer H.
Saleem, Mohamed
Looke, David
Title Therapeutic drug monitoring to adjust dosing in morbid obesity - A new use for an old methodology
Journal name British Journal of Clinical Pharmacology   Check publisher's open access policy
ISSN 0306-5251
1365-2125
Publication date 2012-05
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/j.1365-2125.2011.04159.x
Volume 73
Issue 5
Start page 685
End page 690
Total pages 6
Place of publication Oxford, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2013
Language eng
Abstract The phenomena of hunger and need at one end of the spectrum and obesity and plenty on the other is an anomaly of the 21st century, likely to be due to a combination of distributive inequities in food, social justice, access to education and other socio-economic factors. Both are major problems worldwide, although obesity has more media coverage due to the exponentially increasing incidence and the huge social and economic burden this is placing on Western society. For example, prevalence rates of obesity are currently exceeding 30% of adults in the USA with direct morbidity and mortality complications, in addition to the additional obesity-related health problems and death. Obesity is also rising in children. Obese people are thus a sizable group, and as with those with altered renal or liver function, require specific consideration with respect to the appropriate dosing of medications. However guidelines for how to do this in obesity are not currently available, due to the paucity of literature and regulatory rules for new medications which usually only request the demonstration of average population effectiveness. We believe it is timely for regulatory agencies worldwide to mandate studies involving consideration of body size, particularly obesity, in approving new medications across the therapeutic spectrum. This will drive the pharmaceutical industry to consider these groups in studies and will encourage investigator-initiated research using therapeutic drug monitoring (TDM), target concentration therapy (TCI) and pharmacogenetic (PGx) studies to optimize drug dosing.
Keyword Antimicrobials
Obesity
Therapeutic drug monitoring
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2013 Collection
School of Medicine Publications
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 11 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 07 May 2012, 19:12:56 EST by System User on behalf of School of Medicine